Study on the Effect and Mechanism of Lupatadine Fumarate in the Treatment of Allergic Rhinitis
Launched by CHENG LEI · Nov 27, 2024
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called Lupatadine Fumarate to see how it can help people with allergic rhinitis, which is a common condition that causes sneezing, runny nose, and other allergy symptoms. Allergic rhinitis affects many people in China and can greatly impact their daily lives. The researchers want to understand how Lupatadine works to relieve symptoms, especially nasal congestion, and whether it interacts with certain proteins in the body that are linked to inflammation.
To participate in this study, you must be an adult aged 18 to 65 who has been diagnosed with allergic rhinitis, confirmed through tests for dust mite allergies. However, if you have used certain medications recently, have other nasal or serious health conditions, or are pregnant or a smoker, you may not be eligible. Participants in the trial can expect to receive the medication and be monitored to see how well it works and what effects it has. This research could lead to new and effective treatments for those struggling with allergies.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patients (18-65 years).
- • Patients with allergic rhinitis were diagnosed based on clinical history and positive dust mite sensitization tests (skin prick test and/or specific IgE).
- Exclusion Criteria:
- • Received glucocorticoids, immunomodulatory, antihistamine drugs, and other medications that may affect the study results within the last 1 month.
- • Nasal diseases such as upper respiratory tract infections, chronic sinusitis with or without nasal polyps, and nasal sinus tumors.
- • History of nasal sinus surgery.
- • With other immune and allergic diseases.
- • Patients with a combination of severe cardiac, cerebrovascular or pulmonary - diseases, aspirin triad, primary ciliary dyskinesia, immune deficiency, and coagulation disorders.
- • Pregnant women.
- • Smokers.
About Cheng Lei
Cheng Lei is a dedicated clinical trial sponsor committed to advancing medical research and improving patient outcomes through innovative therapeutic solutions. With a focus on rigorous scientific methodology and adherence to regulatory standards, Cheng Lei collaborates with leading research institutions and healthcare professionals to design and implement clinical trials across various therapeutic areas. Their mission is to accelerate the development of safe and effective treatments while prioritizing patient safety and ethical practices in all aspects of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nanjing, Jiangsu, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported